HBHelen Bitew

Helen Bitew

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Helen Bitew has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development, Characterization, and Evaluation of Topical Antibacterial Formulations From Achyranthes aspera

    by Yohannes Reda Tesfay, Helen Bitew, Fantahun Molla Kassa, Tsadkan Gebremeskel Haile, Huria Hussien Fitwi, Afework Getachew Tadesse, Amanuel Teklebrhan Beyene, Desta Tesfay Mezgebo

    Skin diseases are a significant global health issue, particularly in developing nations. However, the efficiency of topical antibacterial treatments is diminishing due to the development of resistance. This study is aimed at developing and evaluating topical antibacterial formulations from Achyranthes aspera , a plant traditionally used for wound healing. The Kirby–Bauer method was employed to examine the antibacterial activity of hydroalcoholic extracts obtained from fresh and dried leaves of A. aspera . The fraction, which demonstrated the highest antibacterial activity, underwent further testing to determine its minimum inhibitory concentration (MIC) and was employed to formulate eight different topical formulations. These formulations were subsequently evaluated for their antibacterial effectiveness, sensory properties, pH, viscosity, spreadability, and acute dermal toxicity and underwent FTIR compatibility analysis and 3‐month accelerated stability studies (40°C/75% RH). The results indicated that the 70% hydroalcoholic extracts of A. aspera were effective against common skin bacteria, particularly Staphylococcus aureus . Among the fractions tested, the chloroform fraction exhibited the largest zones of inhibition (16.50 ± 0.76 mm for S. aureus and 15.33 ± 0.33 mm for Pseudomonas aeruginosa ) and an MIC of 3.125 mg/mL for both bacteria. Among the eight formulations, the basic cream demonstrated the highest antibacterial performance with a ZI of 19 ± 0.577, followed by the emulsifying ointments. FTIR analysis confirmed the absence of chemical interactions between the active fraction and formulation excipients. All formulations displayed favorable pH levels, good spreadability, homogeneity, and stability and did not cause irritation when applied to mice at a dosage of 2000 mg/kg. The accelerated stability study confirmed that the basic cream and emulsifying ointment maintained their physicochemical properties and antibacterial efficacy over 3 months. The findings suggest that A. aspera chloroform fractions are promising for developing effective topical treatments for S . aureus –related skin infections.


  • Open Access

    Evaluation of the Effect of Hydroethanolic Root Extract and Solvent Fractions of Cyphostemma adenocaule (Steud. ex A. Rich) Descoings ex Wild & Drummond on Cell-Mediated Immune Response and Blood Cell Count in Mice

    by Dehnnet Abebe, Gomathi Periasamy, Aman Karim, Helen Bitew

    Introduction. Cyphostemma adenocaule (Steud. ex A. Rich) Descoings ex wild & Drummond (Vitaceae) has been used in traditional medicine for the management of various immunological and hematological disorders in different areas of Ethiopia and the rest of the world. In Ethiopia, the plant is used for the management of enlarged spleen, rabies virus, helminthic infection, snake bite, and various types of tumors. Objective. To evaluate the effect of hydroethanolic root extract and solvent fractions of Cyphostemma adenocaule on cell-mediated immunity (delayed-type hypersensitivity), organ index (spleen and liver), and blood cell count in Swiss albino mice. Materials and Methods. Acute oral toxicity test was conducted using nulliparous and nonpregnant Swiss albino mice following OECD 425 limit test method. Delayed-type hypersensitivity model was used to evaluate the effect on cell-mediated immunity. The experimental animals were divided into twelve groups which were sensitized and challenged with sheep red blood cells on day 0 and day 7, respectively. Levamisole 50mg/kg was used as stimulant control, whereas cyclophosphamide 30mg/kg was used as suppressant control. Hydroethanolic root extract (100mg/kg, 200mg/kg, and 400mg/kg), aqueous fraction (100mg/kg, 200mg/kg, and 400mg/kg), and n-butanol fraction (100mg/kg, 200mg/kg, and 400mg/kg) were administered for seven days. The paw volume was measured using a digital plethysmometer before challenge and 24 hours after challenge. Blood was collected, and organs (spleen and liver) were isolated from each challenged mouse to determine blood cell count and organ index, respectively. Results. No mortality and noticeable behavioral changes were observed among all mice receiving hydroethanolic root extract and solvent fractions at a dose of 2000mg/kg. Hydroethanolic root extract and solvent fractions of Cyphostemma adenocaule showed enhancement of delayed-type hypersensitivity, organ index, and blood cell count. Hydroethanolic root extract at a dose of 400mg/kg showed the highest and statistically significant stimulation of delayed-type hypersensitivity (0.1230.010) and blood cell count compared to the vehicle. Conclusion. Hydroethanolic root extract and solvent fractions of Cyphostemma adenocaule showed a stimulatory effect on cell-mediated immunity and hematopoiesis.


  • Open Access

    The Outcome of Salt Treatment for Umbilical Granuloma: A Systematic Review

    by Hansa Haftu, Helen Bitew, Atsede Gebrekidan, Hailemariam Gebrearegay

    Background: An umbilical granuloma is one of the common umbilical masses in young children which appears after the cords fall off, mainly due to an inflammatory reaction to subclinical infections. Though there are different recommendations of treatment modalities, which management modality is the best is not clear yet. Objective: This systematic review aimed to assess the effectiveness of salt treatment in terms of complete resolution of the granuloma, any adverse effect, and any recurrence risk in those patients treated as inpatient or outpatient care. Methodology: The literature search was done using search engines including Google scholar, PubMed, and Medlin. Articles published since 1990 and written in the English language with a target population of young children (less than 24 months) were included. To retrieve the articles, umbilical granuloma, treatment of umbilical granuloma, salt treatment, and neonatal umbilical disorder were used as keywords. Results: This systematic review indicated that the majority of the studies done on salt treatment for umbilical granuloma show excellent response (complete resolution of the granuloma/discharge) with no adverse effect and no recurrence in the subsequent follow-up of the patients in almost all cases of the treatment group. Salt inside the occluded hyperosmolar chamber causes shrinkage of granuloma by a desiccant effect. Conclusion: Cooking salt treatment for umbilical granuloma is effective, cheap, available, and easy to apply by non-health professionals. No side effects have been reported yet and a recurrence of the granuloma after treatment seems to be null.


  • Anti-inflammatory and anti-nociceptive property of Capparis tomentosa Lam. root extracts

    by Gebretsadkan Hintsa Tekulu, Teref Hiluf, Hailu Brhanu, Ephrem Mebrahtu Araya, Helen Bitew, Tesfay Haile


  • Open Access

    Does Isoniazid Preventive Therapy Provide Better Treatment Outcomes in HIV-Infected Individuals in Northern Ethiopia? A Retrospective Cohort Study

    by Tesfay Mehari Atey, Helen Bitew, Solomon Weldegebreal Asgedom, Asrat Endrias, Derbew Fikadu Berhe

    Objectives. Early antiretroviral therapy (ART), isoniazid preventive therapy (IPT), and isoniazid-rifapentine (3HP) are effective strategies for preventing tuberculosis (TB) among people living with HIV (PLHIV). The study aimed to determine the effect of IPT on the TB incidence, follow-up CD4+ T cells, and all-cause mortality rate. Participants. Eligible patients on ART (n = 1, 863) were categorized into one-to-two ratios of exposed groups to IPT (n = 621) and nonexposed groups to IPT (n = 1, 242). Exposed groups entered the cohort at their first prescription of IPT, and unexposed groups entered into the study at the first prescription of ART and then followed until the occurrence of the outcome or date of administrative censoring (June 30, 2017). The outcome endpoints were TB incidence, follow-up CD4+ T cells, and all-cause mortality rate. Results. The follow-up CD4+ T cells for the exposed and nonexposed groups were 405.74 and 366.95 cells/mm (World Health Organization (WHO), 2017), respectively, a statistically significant finding (t1861 = −3.770, p<0.0001; Cohen’s d = 0.186). Nine percent of the exposed patients (620 incidence of TB per 100,000 person-years (PYs)) and 21.9% of the nonexposed patients (3160 incidence of TB per 100,000 PYs) developed TB. Mortality rate (per 100,000 PYs) was 440 for the exposed and 1490 for the unexposed patients. Statistically significant determinants of the all-cause mortality were unscheduled follow-up (AHR = 1.601; 95% CI: 1.154–2.222) and unable to work properly (AHR = 2.324; 95% CI: 1.643–3.288). Conclusion. This study demonstrates the effect of IPT in reducing incidence of TB and all-cause mortality rate and improving follow-up CD4+ T cells. Promoting IPT use can help to achieve the TB eradicating national agenda in Ethiopia.


  • Open Access

    Analgesic, Anti-inflammatory and In-vitro Hyaluronidase Inhibitory Properties of the Leaf Extract and Solvent Fractions of Otostegia Fruticosa (Forssk.) Schweinf. ex Penzig

    by Tiegsti Bahta, Aman Karim, Gomathi Periasamy, Gereziher Gebremedhin, Najeeb Naeeb-ur-Rehman, Helen Bitew, Kalay Hagazi

    Otostegia fruticosa is traditionally used to treat tonsillitis, stomach ache, asthma, arthritis, and febrile illness in different parts of Ethiopia and other countries. In this experiment 70% ethanolic crude extract and fractions of the leaf of Otostegia fruticosa (Forssk.) Schweinf. ex Penzig were evaluated for their in-vivo anti-inflammatory and analgesic activities and in-vitro hyaluronidase inhibition properties at different concentrations. Tail immersion, acetic acid induced writhing and carrageenan-induced paw edema model were used to assess the in-vivo analgesic and anti-inflammatory activities, respectively. Swiss albino mice of either sex were randomly divided into five groups of six mice per group and for evaluation of the fractions randomly divided into six groups of six mice per group. The test groups were treated with hydroalcoholic extract of Otostegia fruticosa (O. fruticosa) at doses of 100, 200, and 400 mg/kg. The positive control groups received either pethidine 5 mg/kg or aspirin at 100 mg/kg or 150 mg/kg. The negative control groups were orally given sunflower oil. All the fractions were administered at the dose of 400 mg/kg. In all models, the higher dose (400 mg/kg) of the crude extract and chloroform fraction showed a significant central and peripheral analgesic and anti-inflammatory activities with comparable effects to standards used. The hyaluronidase inhibition assay result showed that the test samples displayed concentration-dependent inhibitory activities. These findings indicate that 70% ethanol extract and organic solvent fractions of O. fruticosa leaves have potential analgesic, anti-inflammatory, and enzyme inhibitory activities.


  • Open Access

    In Vivo Antimalarial Evaluation of Crude Extract, Solvent Fractions, and TLC‐Isolated Compounds from Olea europaea Linn subsp. cuspidata (Oleaceae)

    by Gebretekle Gebremichael Hailesilase, Yarra Rajeshwar, Gebremedhin Solomon Hailu, Gereziher Gebremedhin Sibhat, Helen Bitew

    Malaria is a major global public health problem caused by Plasmodium parasites. Drug resistance is becoming a great challenge. New drugs with novel mechanism of action are urgently required. In malarious countries, medicinal plants are commonly used for malaria treatment. Olea europaea is traditionally used against malaria in Ethiopia. The aim of this study was to isolate and evaluate antimalarial activity of chemical constituents extracted from Olea europaea against chloroquine‐sensitive Plasmodium berghei‐infected mice. Stem bark of Olea europaea was extracted with 80% methanol and fractionated with three solvents. The butanol fraction was subjected to isolation with preparative thin‐layer chromatography (PTLC). Acute oral toxicity studies were conducted in mice as per the Organization for Economic Co‐operation and Development (OECD) guideline 425. Antimalarial activities of the test substances were evaluated using Peter’s 4‐day suppressive test. The crude extract showed significant (p < 0.01) antiplasmodial activity at all doses with a chemosuppression value of 52.40% at a dose of 600 mg/kg. All fractions also suppressed parasitaemia significantly (p < 0.05), the highest suppression (45.42%) being with butanol fraction. In the phytochemical analysis, two compounds were isolated. Both compounds showed significant (p < 0.05) antimalarial activities. Compound C inhibited parasitaemia up to 38.19% at a dose of 200 mg/kg. The crude extract, butanol fraction, and isolated compounds also prolonged survival time of mice. No sign of toxicity and mortality was seen in the test substances at up to a single dose of 2 g/kg. Findings of the current study may confirm the traditional antimalarial claim of Olea europaea and its relative safety as well as the potentiality of compound C for further investigations.


  • Open Access

    Antimicrobial Evaluation of Latex and TLC Fractions from the Leaves of Aloe adigratana Reynolds

    by Demoze Asmerom, Gebremedhin Solomon Hailu, Ebrahim M Yimer, Helen Bitew, Getu Kahsay

    Background. The highest prevalence and emergence of microbial infections coupled with the threat of antimicrobial resistance constitute a global concern, which entails searching for novel antimicrobial agents. Medicinal plants are among the major sources of medicines for novel drug discovery. Aloe adigratana is one of the endemic Aloe species in Ethiopia where the leaf latex of the plant is traditionally used for the treatment of various pathogenic conditions such as wound, dandruff, malaria, and diabetes. In spite of such claims, there was no scientific study done so far. The aim of the current study was, therefore, to evaluate the antimicrobial effect of leaf latex of A. adigratana and its thin layer chromatography (TLC) fractions. Methods. Thin layer chromatography (TLC) separation was employed for isolation of bioactive compounds. Agar well diffusion and microdilution assay method were used to evaluate the antimicrobial actions of the leaf latex and TLC fractions against six bacterial strains and four Candida species of reference and clinical isolate microbial strains. Results. Three major fractions, AA01, AA02, and AA03, were identified by TLC. Among the tested microbial strains, the reference strain of Staphylococcus aureus ATCC 29213 (MIC = 0.06 mg/mL) and clinical Candida krusei 242/18 (MIC = 0.14 mg/mL) exhibited higher susceptibility towards AA02, while reference strains of Klebsiella pneumoniae ATCC 700603 (MIC = 0.19 mg/mL) revealed the highest susceptibility towards AA01. The leaf latex displayed the highest activity against Staphylococcus aureus ATCC 29213 and clinical Candida krusei 242/18 with a MIC value of 0.19 mg/mL. Conclusion. The leaf latex and TLC fractions were found to be active against the tested bacterial and Candida species. Therefore, this finding supports the traditional claim of Aloe adigratana and the need for characterization of the TLC fractions to provide as lead compounds for further comprehensive antibacterial and antifungal activities.


  • Top Cited Papers
    Open Access

    Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017

    by Global Burden of Disease Cancer Collaboration, Christina Fitzmaurice, Degu Abate, Naghmeh Abbasi, Hedayat Abbastabar, Foad Abd-Allah, Omar Abdel-Rahman, Ahmed Abdelalim, Amir Abdoli, Ibrahim Abdollahpour, et al.

    Cancer is now widely recognized as a global problem that unfortunately lacks a global solution. The latest United Nations high-level meeting on noncommunicable diseases (NCDs) exemplified this conundrum.1 Despite global commitment to reducing the risk of and disability from NCDs, including cancer, implementation of known solutions is inadequate to reach the 2011 Political Declaration on the Prevention and Control of Noncommunicable Diseases2,3 (25% reduction in premature mortality from NCDs by 2025) and the third Sustainable Development Goal (by 2030 reduce by one-third premature mortality from NCDs through prevention and treatment, and promote mental health and well-being).4 To reduce cancer burden, identifying the scope of the problem and mapping out implementation of solutions is best done in National Cancer Control Plans (NCCPs). However, a recent review showed that only 29% of low-income countries had a NCCP, and even if NCCPs existed, cost, financing, monitoring, and expansion of information systems was often inadequate. Many highly effective prevention and treatment strategies exist for cancer. However, they are often very specific (eg, vaccination for human papillomavirus and hepatitis B virus for prevention of cervical and liver cancer, or tyrosine kinase inhibitors for cancers with targetable mutations). Effective NCCPs therefore require detailed knowledge about the local burden of cancer and associated risk factors. We herein present results from the Global Burden of Disease (GBD) 2017 study describing cancer incidence, mortality, years of life lost (YLLs), years lived with disability (YLDs), and disability-adjusted life-years (DALYs) for 195 countries from 1990 through 2017, which can inform cancer control through policy, resource allocation, and health system planning.


  • Top Cited Papers
    Open Access

    Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017

    by Tahvi D Frank, Austin Carter, Deepa Jahagirdar, Molly H Biehl, Dirk Douwes-Schultz, Samantha Leigh Larson, Megha Arora, Laura Dwyer-Lindgren, Krista M Steuben, Hedayat Abbastabar, et al.